NEW YORK and SIENA, Italy, Nov. 29, 2012 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. and Philogen S.p.A. today announced that they have commenced pre-clinical development of Philogen's L19 antibody construct labeled with actinium 225 as a therapeutic payload. The L19 antibody targets newly formed blood vessels that otherwise allow cancers to grow.
If successful, this approach will further expand the field of use of alpha emitters. Clinical trials of drug candidates based on alpha emitting isotopes have so far demonstrated significant efficacy with minimal side effects in blood borne cancers, in metastases of solid cancers and in residual disease in solid cancers post-surgery. Actinium Pharmaceuticals and Philogen intend to add antiangiogenesis to this growing field of use of alpha emitters. Antiangiogenesis is a successful approach to treating numerous cancer types. Currently approved antiangiogenesis drugs act mostly by interfering with the signaling pathway used by cancer cells to stimulate growth of blood vessels. In many cases, cancer cells eventually find alternative ways to spur blood vessel growth. In contrast, Philogen's L19 targets adhesion molecules that anchor blood vessel cells which makes it less susceptible to cancer controlled pathways. Depending on the architecture of vasculature and its proximity to cancer stem cells, actinium 225 coupled with L19 could potentially offer an effective combination of properties tailor made for certain solid cancer types. The first model under consideration is glioblastoma multiforme, a difficult to treat form of brain cancer.
"We are looking forward to further demonstrating the power and wide ranging utility of alpha emitters in numerous clinical settings with high unmet medical needs," said Jack Talley, CEO of Actinium Pharmaceuticals.
L19 is Philogen's proprietary monoclonal antibody platform that targets certain isoforms of fibronectin, an adhesion molecule necessary for growth of cancer blood vessels. Philogen has developed several formats of the L19 antibody as well as several antibody-payload combinations to utilize depending on the characteristics of the target cancer's vasculature.
About Actinium 225
Actinium-225 decays by giving off high-energy alpha particles, which kill cancer cells. When actinium decays, it produces a series of daughter atoms, each of which gives off its own alpha particle, increasing the chances that the cancer cell will be destroyed. The technology was first demonstrated by Dr. David Scheinberg at Memorial Sloan Kettering Cancer Center.
About Philogen S.p.A.
Philogen is a Swiss-Italian integrated biotechnology company founded in 1996, with the mission to develop innovative biopharmaceuticals for the treatment of angiogenesis-related disorders. Angiogenesis, i.e. the formation of new blood vessels, is a characteristic feature of many severe pathologies such as cancer, rheumatoid arthritis and age-related macular degeneration.
The company has been a pioneer in the isolation, engineering and clinical development of lead products capable of targeting angiogenesis in-vivo and has been the first in the world to demonstrate that human monoclonal antibodies, specific for a marker of angiogenesis, can efficiently and selectively target the tumor neo-vasculature both in animal models and in cancer patients.
At present, Philogen has four promising anti-cancer antibody derivatives and an antibody-derivative for the treatment of rheumatoid arthritis in clinical studies.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. is a New York, New York based biopharmaceutical company that develops innovative alpha particle immunotherapeutics based on its proprietary platform for the therapeutic utilization of radiopharmaceuticals in association with monoclonal antibodies.
For more information:
Visit our web site www.actiniumpharmaceuticals.com or Contact:
Jack Talley, CEO
Actinium Pharmaceuticals Inc.
Tel: (646) 459-4201
Forward-Looking Statement for Actinium Pharmaceuticals, Inc.
This news release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
SOURCE Actinium Pharmaceuticals, Inc.